NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.
Drugs and Lactation Database (LactMed) [Internet]. Bethesda (MD): National Library of Medicine (US); 2006-.
CASRN: 1370654-58-2
Drug Levels and Effects
Summary of Use during Lactation
Iron isomaltoside 1000 is not approved for marketing in the United States by the U.S. Food and Drug Administration, but is available in other countries. Limited data indicate that breastmilk iron is increased 3 days after an intravenous infusion of iron isomaltoside, but within the normal range. By 7 days after the dose, breastmilk iron levels were similar to that of mothers taking oral iron. Iron isomaltoside 1000 appears to be acceptable to use in nursing mothers with no special precautions required. Pasteurization of milk by the Holder method reduces the concentration of iron in milk by about 6.5%.[1]
Drug Levels
Maternal Levels. Thirty women with postpartum anemia were given intravenous iron isomaltoside 1200 mg in a single intravenous dose over 15 minutes. They were compared to 35 women with postpartum anemia who took 100 mg of oral iron once or twice daily. Breastmilk samples were taken before treatment, 3 (range 2 to 4) days and again at 7 (range 6 to 8) days after the intravenous iron dose. At the 3-day point, the average breastmilk iron concentration was 0.72 mg/L in the IV iron group and 0.4 mg/L in the oral iron group, which was significantly different. At the 7-day point, the average breastmilk iron concentration was 0.47 mg/L in the IV iron group and 0.44 mg/L in the oral iron group, which was not significantly different.[2]
Infant Levels. Relevant published information was not found as of the revision date.
Effects in Breastfed Infants
Relevant published information was not found as of the revision date.
Effects on Lactation and Breastmilk
In a randomized, nonblinded study, randomly assigned to receive either a single intravenous dose of 1200 mg iron isomaltoside (n = 97) or oral iron 40 to 50 mg oral iron daily or 100 mg oral iron one or two times daily (n = 99). There was no significant difference between groups in the median time to lactogenesis, nor in the time of discontinuation of breastfeeding among those who weaned their infants.[3]
Alternate Drugs to Consider
References
- 1.
- Mohd-Taufek N, Cartwright D, Davies M et al. The effect of pasteurization on trace elements in donor breast milk. J Perinatol. 2016;36:897-900. [PubMed: 27253894]
- 2.
- Holm C, Thomsen LL, Norgaard A et al. Iron concentration in breast milk normalised within one week of a single high-dose infusion of iron in randomised controlled trial. Acta Paediatr. 2017;106:256-60. [PubMed: 27883237]
- 3.
- Holm C, Thomsen LL, Norgaard A et al. Single-dose intravenous iron infusion or oral iron for treatment of fatigue after postpartum haemorrhage: A randomized controlled trial. Vox Sang. 2017;112:219-28. [PubMed: 28198084]
Substance Identification
Substance Name
Iron Isomaltoside 1000
CAS Registry Number
1370654-58-2
Drug Class
- Breast Feeding
- Ferric Compounds
- Hematinics
Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.
- User and Medical Advice Disclaimer
- LactMed App
- Drugs and Lactation Database (LactMed) - Record Format
- LactMed - Database Creation and Peer Review Process
- Fact Sheet. Drugs and Lactation Database (LactMed)
- Drugs and Lactation Database (LactMed) - Glossary
- LactMed Selected References
- Drugs and Lactation Database (LactMed) - About Dietary Supplements
- Breastfeeding Links
- PubMedLinks to PubMed
- Review Ferric Carboxymaltose[Drugs and Lactation Database (...]Review Ferric Carboxymaltose. Drugs and Lactation Database (LactMed). 2006
- A comparative study of the physicochemical properties of iron isomaltoside 1000 (Monofer), a new intravenous iron preparation and its clinical implications.[Eur J Pharm Biopharm. 2011]A comparative study of the physicochemical properties of iron isomaltoside 1000 (Monofer), a new intravenous iron preparation and its clinical implications.Jahn MR, Andreasen HB, Fütterer S, Nawroth T, Schünemann V, Kolb U, Hofmeister W, Muñoz M, Bock K, Meldal M, et al. Eur J Pharm Biopharm. 2011 Aug; 78(3):480-91. Epub 2011 Mar 23.
- Iron concentration in breast milk normalised within one week of a single high-dose infusion of iron isomaltoside in randomised controlled trial.[Acta Paediatr. 2017]Iron concentration in breast milk normalised within one week of a single high-dose infusion of iron isomaltoside in randomised controlled trial.Holm C, Thomsen LL, Norgaard A, Markova V, Michaelsen KF, Langhoff-Roos J. Acta Paediatr. 2017 Feb; 106(2):256-260. Epub 2016 Dec 22.
- Introducing iron isomaltoside 1000 (Monofer®)-development rationale and clinical experience.[NDT Plus. 2011]Introducing iron isomaltoside 1000 (Monofer®)-development rationale and clinical experience.Kalra PA. NDT Plus. 2011 Jun; 4(Suppl 1):i10-i13.
- Review Efficacy and safety of iron isomaltoside (Monofer(®)) in the management of patients with iron deficiency anemia.[Int J Nephrol Renovasc Dis. 2016]Review Efficacy and safety of iron isomaltoside (Monofer(®)) in the management of patients with iron deficiency anemia.Kalra PA, Bhandari S. Int J Nephrol Renovasc Dis. 2016; 9:53-64. Epub 2016 Mar 10.
- Iron Isomaltoside 1000 - Drugs and Lactation Database (LactMed)Iron Isomaltoside 1000 - Drugs and Lactation Database (LactMed)
Your browsing activity is empty.
Activity recording is turned off.
See more...